| WHO to help bring cheap biosimilar cancer drugs to poor | | | LONDON (Reuters) - The World Health Organization (WHO) is to launch a pilot project this year to assess cheap copies of expensive biotech cancer drugs in a bid to make such medicines more widely available in poorer countries. |
| |
| Novartis, Roche back French gene therapy start-up Vivet | | | (Reuters) - French gene therapy start-up Vivet Therapeutics said on Thursday it had raised 37.5 million euros ($41 million) in an initial financing round, with backing from the venture arms of Swiss drugmakers Novartis and Roche. |
| |
| Novartis exercises option with Conatus for NASH product | | | ZURICH (Reuters) - Novartis is exercising its option with ConatusPharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said. |
| |
| Aetna adds Virginia to list of Obamacare exits for 2018 | | | NEW YORK (Reuters) - Health insurer Aetna Inc said on Wednesday it will not sell Obamacare individual insurance plans in Virginia next year, a move it attributed to "growing uncertainty" in the market and $200 million in expected losses on the business this year. |
| |
| Bayer, J&J win first trial over Xarelto bleeding risks | | | (Reuters) - A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the first trial to flow out of thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drugmakers said on Wednesday. |
| |
| Imperial Brands could launch heated tobacco product in months if needed | | | LONDON (Reuters) - Britain's Imperial Brands, the fourth-largest international tobacco company, remains committed to its pursuit of e-cigarettes as the best alternative to smoking, but could pivot quickly with a heated tobacco product within months if proved wrong, a senior executive said on Wednesday. |
| |
| | |
